Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | DHFR | P00374 | 8/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | GART | P22102 | 2/20 | 0.51 |
| ▸ | ATIC | P31939 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683754 | 0.92 | TYMS (0.79) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30078194 | 0.91 | TYMS (0.84) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30078267 | 0.91 | AKR1B1 (0.80) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30078340 | 0.89 | TYMS (0.82) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL29907321 | 0.89 | AKR1B1 (0.82) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL470145 | 0.88 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL10173120 | 0.88 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL30174303 | 0.88 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL12523472 | 0.88 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL15094347 | 0.88 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10466253-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170350903-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | US | disclosed |
| US-9778268-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-9720002-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-01 | — | — | US | disclosed |
| US-9043159-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-26 | — | — | US | disclosed |
| US-9037417-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling In Vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140295484-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140295485-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| US-8849581-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140193828-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130273533-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| US-8401800-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120115127-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-10 | — | — | US | disclosed |
| US-8005623-B2 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| CN-100469361-C | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress | NUTRICIA NV (NL) | 2009-03-18 | — | — | CN | disclosed |
| EP-1759326-A4 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | UNIV CALIFORNIA (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1759326-A2 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060020440-A1 | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| CN-1674795-A | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress | NUTRICIA NV (NL) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005081943-A2 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115127-A1 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | GOT2, PC, PCK2 | TYMS 1024/4885AKR1B1 132/4885KDM4E 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.